Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Investment: Sharewatch

Tuesday 25 May 1999 19:02 EDT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

BUY

Buy Anglo American, says both Commerzbank and BT Alex.Brown, at pounds 29.68 and pounds 30.7 respectively. Risks reside in poor information disclosure, South African exchange controls and large crossing holdings, warns BT Alex.Brown, but it praises the simplified group structure, while Commerzbank calculates that the shares are on a 30 per cent discount to Rio Tinto.

OUTPERFORM

J Sainsbury (401p) is set to outperform, argues Morgan Stanley Dean Witter, which has raised its price target by 40p to 450p. MSDW points out that Sainsbury's and Safeway's real estate is valued more highly in the property market than by the equity market, suggesting that a cheap way into UK food retail sector is via the stock market. If Asda's is worth the price Kingfisher is paying, J S should be valued at 468p-555p.

HOLD

Glaxo Wellcome's trading update for the first four months of 1998 was disappointing, says Sutherlands, which has cut its recommendation on the pharmaceuticals giant from buy to hold (1809p). Glaxo's target of double digit growth in 1999 is likely to be a challenge.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in